Business Wire

OR-CIRIUM

3.6.2021 13:02:11 CEST | Business Wire | Press release

Share
US Travelers Confident to Return to Skies and Business Travel Poised for Fall Comeback, Reveals Cirium Survey

Americans are confident to fly again, with 78% of travelers intending to travel for leisure, according to results from a new survey from Cirium , the aviation analytics company. Of those who travel for business, 67% indicate their employer will permit travel in the next three to six months. Some 40% of respondents who intend to return to the skies plan to fly this summer. However, only a small minority had plans to travel by air for major holidays such as the July 4th weekend (16%) and Labor Day weekend (17%).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005493/en/

The firm interviewed 2,140 adults across the US between May 11 and 17, 2021, in a nationally representative sample. The margin of error in the reported data did not exceed +/- 3% at the 95% confidence level.

A strong majority of US travelers (90%) intend to fly at some point in the future, and 64% are planning to fly within the next 12 months.

More than three-quarters (78%) of those with plans to travel this year are only planning for domestic trips. Only 22% expect to fly internationally in 2021. The survey also reveals that over one-quarter of respondents reported having taken a flight since the pandemic. Some 60% of respondents indicated that the pandemic will have no impact on their long-term travel plans.

“Cirium’s traveler survey identifies the confidence of the US in flying again, with a majority taking to the skies domestically already—mainly to visit family. The results indicate that the challenges facing US airlines is not lack of travel demand, but on the health and safety measures in place at the airport and in flight,” said Jeremy Bowen, CEO at Cirium.

“US business travel may see some green shoots of recovery in the fall of 2021, as corporations plan to release restrictions on travel.”

While US airlines are increasing domestic flights for summer 2021 and Americans show interest in flying again, travelers expressed health and safety concerns, which impact their travel decisions.

Respondents strongly support the adoption of health passports for future air travel, with 59% supporting a requirement to carry mandatory passes to fly—though 20% disagree with the idea. When asked what airline measures would increase their motivation to fly, the majority of participants identified mandatory mask-wearing (61%) and improved cleaning processes (61%) as the top two measures.

The majority of respondents (78%) identify leisure travel as the main purpose for travel, however the survey reveals optimism for business travel returning in the fall.

Of the respondents who said they travel for business, just 34% were currently permitted to travel by their employer, increasing to 67% within the next three to six months.

The rise in working from home seems to have had little effect on the likelihood to travel for business reasons, as half of US respondents claim there is no change and nearly a quarter (24%) said they are more likely to travel for business.

More than half the respondents reported that they could work remotely and 40% of these respondents claim that the pandemic has increased the chances that they would combine a vacation with work.

Additional insights on air travel in the full report:

- Awareness of new startup airlines in the US

- Long-haul flying on single-aisle aircraft

- Lounge usage and time spent at the airport

- The influence of sustainability concerns on travel

Click here to see the full US Cirium Traveler Intelligence Report.

Complete data with results by age group, US region and gender available on request. Similar data for the UK is available. The survey into traveler sentiment was carried out by independent market intelligence firm AudienceNet on behalf of Cirium.

Ends

For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye